ArticlePloS one2026
UHPLC-QTOF-MS/MS-based metabolomic discovery of anticancer compounds in ethanolic extracts of Ficus hispida L. f.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dichloromethane fraction from Ficus hispida L.f. fruit extract suppresses lung cancer through cell cycle arrest and TNF-induced apoptosis.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ficus hispida L. f. (F. hispida) is commonly used in traditional medicine for various health problems. No comprehensive analysis of all its components has yet been undertaken, despite researchers having explored its chemical constituents and biological activities. Using untargeted metabolomics, we aimed to assess the chemical compositions and metabolic differences among the five parts of F. hispida: bark, fruits, leaves, twigs, and stalks. To discover the compounds that might be accountable for the noted efficacy, our study assessed the correlation between the identified metabolites and anticancer activities. We applied untargeted metabolomics using UHPLC-QTOF-MS/MS to confirm a total of 82 metabolites. These compounds were classified into six phytochemical groups with predominant accumulation in each part: fatty acids and their conjugates (twigs), terpenoids (stalks), phenylpropanoids (bark and twigs), alkaloids (bark and leaves), saccharides and their conjugates (bark), and amino acids and peptides (twigs and stalks). Multivariate analysis showed markedly distinct metabolic patterns across the five tested parts, especially leaf and bark extracts. The sulforhodamine assay (SRB) for the cytotoxicity test revealed that the bark and leaf extracts had the highest potential to inhibit the viability of cholangiocarcinoma (CCA) cells, with IC50 values of 0.71 ± 0.17 µg/mL and 0.82 ± 0.22 µg/mL for KKU-213A, and 0.78 ± 0.13 µg/mL and 1.03 ± 0.21 µg/mL for KKU-055. Univariate analysis revealed that four metabolites, including catharanthine, cianidanol, procyanidin B2, and quinic acid, had significant correlation with these anticancer abilities. Subsequent cytotoxicity studies on these candidate metabolites revealed that catharanthine suppressed CCA cell viability at the IC50 of 41.0 ± 0.99 µM (KKU-213A) and 47.4 ± 4.34 µM (KKU-055) over other candidates. Our research suggests that catharanthine, which is a terpene indole alkaloid found in the bark and leaves of F. hispida, is responsible for the anticancer efficacy against CCA cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.